CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (10,622)	$ (9,414)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	12	25
Stock-based compensation expense	728	3,623
Non-cash interest expense - related party		121
Change in fair value of warrant liability	4,851
Changes in operating assets and liabilities, net of impact of assumed net assets of Macrocure:
Prepaid expenses and other assets	(117)	(70)
Research and development incentive receivable	89	(397)
Accounts payable and accrued expenses	(419)	(237)
Net cash used in operating activities	(5,478)	(6,349)
Cash flows from investing activities:
Purchases of property and equipment		(65)
Net cash used in investing activities		(65)
Cash flows from financing activities:
Proceeds from issuance of common stock in connection with merger with Macrocure		21,165
Proceeds from issuance of common stock in connection with Subscription Agreement		10,000
Proceeds from the issuance of common stock, net of underwriter commissions and discounts	15,033
Proceeds from notes payable - related party		750
Payment of deferred offering costs	(28)	(2,067)
Net cash provided by financing activities	15,005	29,848
Effect of exchange rate changes on cash and cash equivalents	112	(427)
Net increase in cash and cash equivalents	9,639	23,007
Cash and cash equivalents at beginning of period	25,737	793
Cash and cash equivalents at end of period	35,376	23,800
Supplemental disclosure of non-cash financing activities:
Accretion of preferred stock to redemption value		244
Offering costs included in accounts payable and accrued expenses	$ 210
Conversion of notes payable - related party and accrued interest into common stock		31,145
Conversion of convertible preferred stock into common stock		70,775
Value of net assets acquired in connection with merger with Macrocure, excluding cash		$ 96